04Apr 2023
Combination of Proclarix and MRI leads to highly accurate prostate cancer diagnosis

Combination of Proclarix and MRI leads to highly accurate prostate cancer diagnosis

The study aimed to assess the clinical performance of Proclarix®, a biomarker test for identifying clinically significant prostate cancer (csPCa) in combination with multiparametric magnetic resonance imaging (mpMRI) or alone. The study included blood samples from 721 men undergoing mpMRI followed by biopsy. The Proclarix-MRI model was trained on a cohort of 159 men and validated on a cohort of 562 men, with diagnostic performance established in correlation to biopsy outcome. The results showed that Proclarix reliably predicted csPCa and ruled out men with no or indolent cancer when combined with mpMRI and prostate volume, resulting in a large reduction of two-thirds of unneeded biopsies. Proclarix can also be used with high confidence to reliably detect csPCa in men with an indeterminate PI-RADS score 3 mpMRI.

  • #urology

Like

Save

Share